Home › Research › Tau biomarkers
Analytical Qualification of the BD‐Tau Xplorer kit on LUMIPULSE® G1200
Jeroen Vanbrabant, Maxime Van Loo, Nathan Blancke, Daniel Antwi‐Berko, Wiesje M. van der Flier, Inge M.W. Verberk, Charlotte Elisabeth Teunissen, Erik Stoops. Alzheimer s & Dementia, 2025-12-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
The assay demonstrated robust quantification of BD-Tau in CSF, plasma, and serum with measured concentrations ranging from 3 to 20 pg/mL across 15 paired plasma and serum samples. Serum levels were ∼10% lower than plasma concentrations but showing strong correlation (Spearman r = 0.74; p = 0.002). Median intra- and inter-assay CV% were below 10% across six independent runs with measurements done in duplicate, on calibrator, spiked buffer and plasma samples. The LLOQ was determined to be 0.78 pg/mL based on precision profile. Lot-to-lot variability was below 10%. Significant correlation with the BD-Tau SIMOA assay was observed (Spearman r = 0.89; p < 0.0001), with superior discriminatory power for AD versus controls in a first exploratory assessment using the plasma samples (Xplorer assay AUC: 0.69 vs SIMOA assay AUC: 0.59). The BD-Tau Xplorer kit provides accurate and reproducible quantification of BD-Tau on an automated platform. Further validation in larger and more differentiated cohorts is warranted to evaluate its context of use and value as a potential marker for prognosis and monitoring disease progression, not only in AD but across neurological diseases.
What this study adds
Evidence grade: Moderate
The authors state that further validation in larger and more differentiated cohorts is needed before its value as a marker for prognosis and monitoring can be established, and no treatment or cure is reported. Reported effect size: AUC: 0.69; AUC: 0.59.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Vanbrabant, J., Van Loo, M., Blancke, N., Antwi‐Berko, D., van der Flier, W. M., Verberk, I. M., et al. (2025). Analytical Qualification of the BD‐Tau Xplorer kit on LUMIPULSE® G1200. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_105432
Vancouver
Vanbrabant J, Van Loo M, Blancke N, Antwi‐Berko D, van der Flier WM, Verberk IM, et al. Analytical Qualification of the BD‐Tau Xplorer kit on LUMIPULSE® G1200. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_105432. PMID: 41518608.
BibTeX
@article{vanbrabant2025-41518608,
author = {Vanbrabant, Jeroen and Van Loo, Maxime and Blancke, Nathan and Antwi‐Berko, Daniel and van der Flier, Wiesje M. and Verberk, Inge M.W. and Teunissen, Charlotte Elisabeth and Stoops, Erik},
title = {{Analytical Qualification of the BD‐Tau Xplorer kit on LUMIPULSE® G1200}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_105432},
pmid = {41518608},
url = {https://doi.org/10.1002/alz70856_105432}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- The assay demonstrated robust quantification of BD-Tau in CSF, plasma, and serum with measured concentrations ranging from 3 to 20 pg/mL across 15 paired plasma and serum samples.
- Serum levels were ∼10% lower than plasma concentrations but showing strong correlation (Spearman r = 0.74; p = 0.002).
- Median intra- and inter-assay CV% were below 10% across six independent runs with measurements done in duplicate, on calibrator, spiked buffer and plasma samples.
- The LLOQ was determined to be 0.78 pg/mL based on precision profile.
- Significant correlation with the BD-Tau SIMOA assay was observed (Spearman r = 0.89; p < 0.0001), with superior discriminatory power for AD versus controls in a first exploratory assessment using the plasma samples (Xplorer assay AUC: 0.69 vs SIMOA assay AUC: 0.59).
Why it matters
This study describes the analytical qualification of the BD-Tau Xplorer kit on an automated platform, showing accurate and reproducible measurement of BD-Tau in cerebrospinal fluid, plasma and serum, with an exploratory assessment showing better discrimination of Alzheimer's disease versus controls than a comparison assay. The authors state that further validation in larger and more differentiated cohorts is needed before its value as a marker for prognosis and monitoring can be established, and no treatment or cure is reported.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Effect sizeAUC: 0.69; AUC: 0.59
- Evidence strengthModerate
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Erik Stoops: h-index 34 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Vrije Universiteit Amsterdam: institution h-index 1,014 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41518608) |
| Free to read | 2 / 2 | Free to read |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70856_105432
- PubMed: 41518608
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Tau biomarkers from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.